CHD
MCID: CRN300
MIFTS: 73

Coronary Heart Disease 1 (CHD)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Muscle diseases

Aliases & Classifications for Coronary Heart Disease 1

MalaCards integrated aliases for Coronary Heart Disease 1:

Name: Coronary Heart Disease 1 57 29 6 37
Coronary Heart Disease 57 74 29 54 6 62 71
Coronary Heart Disease, Susceptibility to, 1 57 71
Coronary Heart Disease, Susceptibility to 57 13
Heart, Coronary, Disease, Susceptibility to, Type 1 39
Coronary Arteriosclerosis 71
Coronary Artery Disease 71
Chds1 57
Chd 48

Classifications:



External Ids:

OMIM® 57 607339
UMLS 71 C0010054 C0010068 C1846418 more

Summaries for Coronary Heart Disease 1

PubMed Health : 62 About coronary heart disease: Coronary heart disease (CHD) is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle. When plaque builds up in the arteries, the condition is called atherosclerosis (ATH-er-o-skler-O-sis). The buildup of plaque occurs over many years.

MalaCards based summary : Coronary Heart Disease 1, also known as coronary heart disease, is related to angina pectoris and abdominal obesity-metabolic syndrome 1, and has symptoms including tremor, angina pectoris and chest pain. An important gene associated with Coronary Heart Disease 1 is CX3CR1 (C-X3-C Motif Chemokine Receptor 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Folate Metabolism. The drugs Hydromorphone and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include Bone and Limb, and related phenotypes are Decreased free cholesterol and Decreased LDL uptake

Wikipedia : 74 Coronary artery disease (CAD), also called coronary heart disease (CHD), ischemic heart disease (IHD),... more...

More information from OMIM: 607339

Related Diseases for Coronary Heart Disease 1

Diseases in the Coronary Heart Disease 1 family:

Coronary Heart Disease 3 Coronary Heart Disease 2
Coronary Heart Disease 4 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 8
Coronary Heart Disease 9 Coronary Heart Disease 6

Diseases related to Coronary Heart Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 737)
# Related Disease Score Top Affiliating Genes
1 angina pectoris 32.5 INS CRP APOA1 ACE
2 abdominal obesity-metabolic syndrome 1 32.0 LPL INS APOB APOA1
3 hypercholesterolemia, familial, 2 32.0 LDLR APOE APOB
4 intermediate coronary syndrome 31.8 INS CRP APOB APOA1 ACE
5 hyperlipoproteinemia, type iii 31.7 LPL LDLR HMGCR CETP APOE APOB
6 heart disease 31.5 PON1 LPL LDLR INS HMGCR CX3CR1
7 glucose intolerance 31.4 LPL INS CRP ACE
8 hyperuricemia 31.4 INS CRP APOB
9 homocysteinemia 31.4 PON1 CRP APOE
10 hypercholesterolemia, familial, 1 31.3 LPL LDLR INS HMGCR CRP COG2
11 anxiety 31.3 INS CRP APOE ACE
12 acute myocardial infarction 31.3 HMGCR CRP APOB APOA1 ACE
13 hypertriglyceridemia, familial 31.2 LPL INS CETP APOE APOC3 APOB
14 peripheral vascular disease 31.2 HMGCR CRP CETP APOB APOA1 ACE
15 pulmonary disease, chronic obstructive 31.1 INS HMGCR CRP ACE
16 coronary stenosis 31.1 PON1 LPL CRP CETP APOE APOB
17 hyperlipidemia, familial combined, 3 31.1 PON1 LPL LDLR INS HMGCR COG2
18 stroke, ischemic 31.1 PON1 LDLR HMGCR CRP APOE APOB
19 sleep apnea 31.0 INS CRP APOE APOB ACE
20 lipoprotein quantitative trait locus 31.0 PON1 LPL LDLR INS HMGCR CX3CR1
21 intermittent claudication 31.0 LPL CRP ACE
22 peripheral artery disease 31.0 CRP APOE APOB APOA1 ACE
23 carotid stenosis 31.0 CRP APOE ACE
24 microvascular complications of diabetes 5 30.9 PON1 INS ACE
25 end stage renal disease 30.8 PON1 INS CRP APOB ACE
26 arteries, anomalies of 30.8 INS CRP APOE APOB APOA1 ACE
27 atherosclerosis susceptibility 30.8 PON1 LPL INS HMGCR CX3CR1 CRP
28 cerebrovascular disease 30.8 PON1 LPL INS CX3CR1 CRP APOE
29 arteriosclerosis 30.7 PON1 INS HMGCR CRP APOE APOB
30 hypothyroidism 30.7 PON1 INS CRP CETP APOB APOA1
31 familial hypercholesterolemia 30.7 PON1 LPL LDLR INS HMGCR CRP
32 myocardial infarction 30.7 PON1 LPL INS HMGCR CRP CETP
33 tangier disease 30.7 LPL CETP APOE APOB APOA1
34 hemochromatosis, type 1 30.7 PON1 INS HMGCR CX3CR1
35 chronic kidney disease 30.7 PON1 LPL INS CRP CETP APOE
36 silent myocardial infarction 30.7 INS CRP APOB APOA1 ACE
37 aortic valve disease 2 30.6 CRP APOB ACE
38 vascular disease 30.6 PON1 LPL INS HMGCR CX3CR1 CRP
39 non-alcoholic fatty liver disease 30.6 LPL INS HMGCR CRP APOE APOC3
40 sleep disorder 30.6 INS CRP APOE ACE
41 aortic aneurysm, familial abdominal, 1 30.5 CRP CETP APOE ACE
42 lipid metabolism disorder 30.5 PON1 LPL LDLR INS HMGCR CRP
43 osteoporosis 30.5 INS HMGCR CRP APOE APOB ACE
44 generalized atherosclerosis 30.5 INS CRP APOE APOB ACE
45 apnea, obstructive sleep 30.5 INS CRP APOE ACE
46 prediabetes syndrome 30.5 INS CRP APOB APOA1
47 aortic dissection 30.5 LDLR CRP ACE
48 type 2 diabetes mellitus 30.5 PON1 LPL INS HMGCR CRP COG2
49 arcus corneae 30.5 LDLR APOB APOA1
50 aortic atherosclerosis 30.5 PON1 LPL CETP APOE ACE

Graphical network of the top 20 diseases related to Coronary Heart Disease 1:



Diseases related to Coronary Heart Disease 1

Symptoms & Phenotypes for Coronary Heart Disease 1

Clinical features from OMIM®:

607339 (Updated 05-Mar-2021)

UMLS symptoms related to Coronary Heart Disease 1:


tremor, angina pectoris, chest pain, edema, equilibration disorder, substernal pain

GenomeRNAi Phenotypes related to Coronary Heart Disease 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.65 LDLR
2 Decreased LDL uptake GR00340-A-1 8.62 LDLR LPL

MGI Mouse Phenotypes related to Coronary Heart Disease 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.23 ACE APOA1 APOB APOE HMGCR INS

Drugs & Therapeutics for Coronary Heart Disease 1

PubMed Health treatment related to Coronary Heart Disease 1: 62

Treatments for coronary heart disease (CHD) include lifestyle changes, medicines, and medical procedures. Treatment goals may include: Relieving symptoms. Reducing risk factors in an effort to slow, stop, or reverse the buildup of plaque . Lowering the risk of blood clots forming. (Blood clots can cause a heart attack .) Widening or bypassing clogged arteries . Preventing complications of CHD.

Drugs for Coronary Heart Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 649)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
2
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
3
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
4
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
5
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
6
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
7
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
8
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
9
Fenofibrate Approved Phase 4 49562-28-9 3339
10
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
11
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
12
Nitric Oxide Approved Phase 4 10102-43-9 145068
13
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
14
Polyestradiol phosphate Approved Phase 4 28014-46-2
15
Atenolol Approved Phase 4 29122-68-7 2249
16
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
17
Insulin aspart Approved Phase 4 116094-23-6 16132418
18
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
19
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
22
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
23
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
24
Eplerenone Approved Phase 4 107724-20-9 150310 443872
25
Iodine Approved, Investigational Phase 4 7553-56-2 807
26
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
27
Probucol Approved, Investigational Phase 4 23288-49-5 4912
28
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
29
Etomidate Approved Phase 4 33125-97-2 36339 667484
30
Glimepiride Approved Phase 4 93479-97-1 3476
31
Famotidine Approved Phase 4 76824-35-6 3325
32
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
33
Ramipril Approved Phase 4 87333-19-5 5362129
34
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
35
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
36
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
37
Insulin glargine Approved Phase 4 160337-95-1
38
Linagliptin Approved Phase 4 668270-12-0 10096344
39
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
40
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
41
Glyburide Approved Phase 4 10238-21-8 3488
42
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
43
Abciximab Approved Phase 4 143653-53-6
44
Remifentanil Approved Phase 4 132875-61-7 60815
45
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
46
Ticlopidine Approved Phase 4 55142-85-3 5472
47
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
48
Cosyntropin Approved Phase 4 16960-16-0 16129617
49
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
50
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754

Interventional clinical trials:

(show top 50) (show all 4364)
# Name Status NCT ID Phase Drugs
1 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
2 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
3 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
4 Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study - Unknown status NCT01453712 Phase 4
5 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
6 Evaluation of the Strategy of "One-stop" Endovascular Treatment for Concomitant Coronary Artery Disease and Aortic Atherosclerotic Disease Unknown status NCT03563768 Phase 4
7 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
8 A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
9 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
10 Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus. Unknown status NCT01735825 Phase 4
11 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
12 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
13 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
14 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
15 Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study Unknown status NCT03679091 Phase 4 low-dose ticagrelor;Clopidogrel
16 Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study Unknown status NCT00513149 Phase 4 Clopidogrel
17 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
18 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
19 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
20 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
21 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
22 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
23 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
24 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
25 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
26 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
27 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
28 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
29 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
30 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
31 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
32 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
33 Cardiac Metabolic Modulator Treatment for Improvement of Left Ventricular Diastolic Function in Patients With Coronary Heart Disease: a Prospective, Randomized Controlled Study Unknown status NCT03887013 Phase 4 Trimetazidine
34 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
35 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
36 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
37 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
38 Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study Unknown status NCT01233453 Phase 4
39 A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS. Unknown status NCT01918150 Phase 4
40 Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography Unknown status NCT01023919 Phase 4
41 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
42 Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
43 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
44 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
45 Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial) Unknown status NCT02501616 Phase 4 Metformin;Dapagliflozin
46 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
47 Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound Unknown status NCT03529253 Phase 4 Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily;Rosuvastatin calcium10mg
48 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
49 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
50 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel

Search NIH Clinical Center for Coronary Heart Disease 1

Inferred drug relations via UMLS 71 / NDF-RT 51 :


atorvastatin
Atorvastatin calcium
cerivastatin
Cerivastatin sodium
Cholestyramine Resin
Clofibrate
colesevelam
Colesevelam hydrochloride
Colestipol
Colestipol Hydrochloride
Dextrothyroxine
Dextrothyroxine Sodium
eptifibatide
Fenofibrate
Fish Liver Oils
fluvastatin
Fluvastatin sodium
Gemfibrozil
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Lovastatin
Pravastatin
Pravastatin Sodium
Probucol
rosuvastatin
Simvastatin
Sulfinpyrazone
tirofiban
TIROFIBAN HYDROCHLORIDE

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Coronary Heart Disease 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Coronary Heart Disease 1:
ACT34-CMI, bone marrow-derived cells for ischemic heart diseases
Adipocell, adipose-derived stem cells for chronic ischemic cardiomyopathy
Adipose-derived mesenchymal stromal stem cells for ischemic heart disease
ADRCs, adipose-derived regenerative cells for cardiovascular disease
ALD-201, bone marrow-derived cells for coronary artery disease
AMDC, autologous muscle-derived cells for ischemic heart failure
Autologous bone marrow-derived mesenchymal stem cells for treatment of heart muscle damage
Bone marrow-derived CD133+ stem cells for treatment of ischemic heart disease
Bone marrow-derived mesenchymal stem cells for treatment of heart diseases
Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy
Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy during artery bypass grafting
Bone marrow-derived mesenchymal stem cells for treatment of ischemic heart disease
Bone marrow-derived mononuclear cells for ischemic cardiomyopathy
Bone marrow-derived mononucleated cells for heart disease
Bone marrow-derived stem cells for treatment of chronic ischemic heart failure
Bone marrow-derived stem cells for treatment of ischemic cardiomyopathy
Bone marrow-derived stem cells for treatment of severe chronic ischemic heart disease
Cardiac stem cells for treatment of ischemic cardiomyopathy
Cardiocell, bone marrow-derived mesenchymal stem cells for heart diseases
Combination therapy of mononuclear cells with laser for coronary disease
Embryonic stem cell-derived cardiomyocytes for ischemic myocardium
Enriched bone marrow-derived progenitor cells for heart diseases
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Mesendo, stem cell combination for treatment of cardiovascular diseases
Peripheral mononuclear cells CD34+ stem cells for treatment of myocardial ischemia
Peripheral or bone marrow-derived stem cells for chronic heart failure
StempeucelICM, mesenchymal stem cells for ischemic cardiomyopathy
Embryonic/Adult Cultured Cells Related to Coronary Heart Disease 1:
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 22163120 9020076 20448213 12551872 11283669 21737787 17562958
VEGF-A165-stimulated ADSCs
Adipose-derived stem and regenerative cells PMIDs: 22281257 21082397
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 19627297 10430905
Autologous muscle-derived cells
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 21052537 19591227
Bone marrow-derived CD133+ cells
Bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602
Bone marrow-derived hematopoietic stem cells (family)
Bone marrow-derived stem cells
Bone marrow-derived mononuclear cells (family) PMIDs: 22940024 21392602
Porcine bone marrow-derived mesenchymal stem cells PMIDs: 22940024 21392602
Human cardiac stem cells PMIDs: 22088800 22965994
Cardiomyocyte-like cells PMIDs: 18941512
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 16990384 18794392 22936827 23362308
Bone marrow-derived mononuclear cells PMIDs: 21323410 20631864
Bone marrow-derived mesenchymal stem cells PMIDs: 21323410 20631864
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mononuclear cells PMIDs: 20668107 21596713 19761394 22834565
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444

Genetic Tests for Coronary Heart Disease 1

Genetic tests related to Coronary Heart Disease 1:

# Genetic test Affiliating Genes
1 Coronary Heart Disease 1 29 CX3CR1
2 Coronary Heart Disease 29

Anatomical Context for Coronary Heart Disease 1

MalaCards organs/tissues related to Coronary Heart Disease 1:

40
Heart, Endothelial, Bone Marrow, Kidney, Bone, Liver, Thyroid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Coronary Heart Disease 1:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Coronary Heart Disease 1

Articles related to Coronary Heart Disease 1:

(show top 50) (show all 30688)
# Title Authors PMID Year
1
A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. 61 57
11734540 2001
2
LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP. 6
21146168 2011
3
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. 57
20886236 2011
4
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. 57
20933357 2010
5
KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. 57
20854963 2010
6
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 57
17554300 2007
7
Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins. 6
10517255 1999
8
Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study. 6
10364086 1999
9
The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. 6
8199176 1994
10
Effect of statin therapy on leptin levels in patients with coronary heart disease. 61 54
20338208 2010
11
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. 54 61
20479152 2010
12
Genetic and environmental determinants of total and high-molecular weight adiponectin in families with low HDL-cholesterol and early onset coronary heart disease. 54 61
20056223 2010
13
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. 61 54
20452521 2010
14
Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. 61 54
20207770 2010
15
Demographic and cardiovascular risk factors modify association of fasting insulin with incident coronary heart disease and ischemic stroke (from the Atherosclerosis Risk In Communities Study). 54 61
20451688 2010
16
Does interleukin-18 or tumour necrosis factor-alpha have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand. 61 54
20096599 2010
17
Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. 54 61
20379055 2010
18
Association between the interleukin-6 gene -572G/C and -597G/A polymorphisms and coronary heart disease in the Han Chinese. 54 61
20190679 2010
19
Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. 61 54
20339975 2010
20
Serum adiponectin and resistin levels in major depressive disorder. 54 61
19694629 2010
21
Evaluation of serum levels of C-reactive protein and lipid profiles in patients with chronic periodontitis and/or coronary heart disease in an ethnic Han population. 61 54
20213025 2010
22
Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. 61 54
19781705 2010
23
Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984-2002. 54 61
19732895 2010
24
Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. 61 54
19936703 2010
25
Higher level of systemic C-reactive protein is independently predictive of coronary heart disease in older community-dwelling adults: the three-city study. 54 61
20002508 2010
26
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 54 61
20031199 2010
27
Influence of genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and M1 (GSTM1) on hematological parameters. 54 61
19662515 2010
28
Association of LT-alpha Ala252Gly gene polymorphism and the genetic predisposition of coronary heart disease in Chinese. 54 61
19365711 2010
29
Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. 61 54
19473179 2010
30
Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. 54 61
19669729 2009
31
Glucocorticoid receptor gene and depression in patients with coronary heart disease: the Heart and Soul Study-2009 Curt Richter Award Winner. 54 61
19783104 2009
32
Association of cystatin C with ischemia in patients with coronary heart disease. 54 61
19816865 2009
33
Evaluating the causal relevance of diverse risk markers: horizontal systematic review. 54 61
19892791 2009
34
Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. 54 61
19863872 2009
35
P-selectin gene polymorphisms and risk of coronary heart disease among Tunisians. 54 61
19082691 2009
36
[Effect of renshen jianxin capsule for alleviating insulin resistance in patients with coronary heart disease and glucose tolerance impairment]. 54 61
19960983 2009
37
The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents. 61 54
19325541 2009
38
Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. 61 54
19732605 2009
39
APOE genotype, lipids, and coronary heart disease risk: a prospective population study. 61 54
19667307 2009
40
Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease. 61 54
19215239 2009
41
[Association between hemoglobin scavenger receptor CD163 expression and coronary atherosclerotic severity in patients with coronary heart disease]. 54 61
19961729 2009
42
Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. 61 54
19111833 2009
43
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. 61 54
19567438 2009
44
The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. 61 54
19411665 2009
45
Expression of heat shock proteins and nitrotyrosine in small arteries from patients with coronary heart disease. 61 54
19626397 2009
46
Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. 61 54
20031597 2009
47
Does a gene polymorphism predisposing to an intermediate phenotype predict the risk of disease? A lesson from CETP, high-density lipoprotein-cholesterol and coronary heart disease. 61 54
19465783 2009
48
Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. 54 61
19673941 2009
49
Cystatin C associates with arterial stiffness in older adults. 54 61
19357259 2009
50
Role of apolipoproteins E and A-I: epistatic villains of triglyceride mediation in coronary heart disease. 61 54
18378026 2009